KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has disclosed Other Gross PP&E Adjustments for 16 consecutive years, with $7.2 billion as the latest value for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 13.7% year-over-year to $7.2 billion; the TTM value through Dec 2025 reached $7.2 billion, up 13.7%, while the annual FY2025 figure was $7.2 billion, 13.7% up from the prior year.
  • Other Gross PP&E Adjustments hit $7.2 billion in Q4 2025 for Regeneron Pharmaceuticals, up from $6.3 billion in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $7.2 billion in Q4 2025 and bottomed at -$15.6 million in Q3 2022.
  • Average Other Gross PP&E Adjustments over 5 years is $4.7 billion, with a median of $5.2 billion recorded in 2022.
  • Year-over-year, Other Gross PP&E Adjustments grew 13.25% in 2022 and then grew 14.71% in 2023.
  • Regeneron Pharmaceuticals' Other Gross PP&E Adjustments stood at $4.2 billion in 2021, then grew by 13.25% to $4.8 billion in 2022, then increased by 14.71% to $5.5 billion in 2023, then grew by 14.06% to $6.3 billion in 2024, then rose by 13.7% to $7.2 billion in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $7.2 billion, $6.3 billion, and $5.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.